<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30636" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tropicamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hong</surname>
            <given-names>Diana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Diana Hong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30636.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tropicamide is a safe drug for pupillary dilation before a comprehensive eye exam or ocular procedure. Pupillary dilation is also necessary for specific intraocular procedures such as cataract surgery to reduce intraoperative complications and for better exposure to the cataract during surgery. Pupillary dilation is also essential for retinal surgery and investigations of the posterior segment. The use of mydriatic agents such as tropicamide has, therefore, become ubiquitous in optical settings. This activity will review drug indications, mechanisms of action, side effects, and how an interprofessional approach can improve patient management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for tropicamide</p></list-item><list-item><p>Summarize the mechanism through which tropicamide acts in each indication</p></list-item><list-item><p>Review the adverse effects of tropicamide, including at-risk patients for which prescribers require extra caution.</p></list-item><list-item><p>Explain some interprofessional team strategies for improving care coordination and communication to advance tropicamide where it is indicated and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30636&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30636">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30636.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intended for diagnostic purposes: to achieve mydriasis</p>
          </list-item>
        </list>
        <p>The preferred practice pattern of the American Academy of Ophthalmology recommends periodic dilated eye exams in different age groups.<xref ref-type="bibr" rid="article-30636.r1">[1]</xref></p>
        <p>Achieving a clinically effective pupil diameter of 6 mm is essential for viewing structures in the posterior segment. The most common indication for a comprehensive exam with pupillary dilation is screening for diabetic retinopathy. The nondilated exam gives the correct classification for the presence or stage of diabetic retinopathy in only&#x000a0; 50% of cases.<xref ref-type="bibr" rid="article-30636.r2">[2]</xref>&#x000a0;Pupillary dilation is necessary for specific intraocular procedures such as cataract surgery to reduce intraoperative complications and for better exposure to the cataract during surgery.<xref ref-type="bibr" rid="article-30636.r3">[3]</xref> Pupillary dilation is also necessary for retinal surgery and investigations of the posterior segment. The use of mydriatic agents such as tropicamide has, therefore, become ubiquitous in each optical setting. Tropicamide comes in two formulations, 0.5% and 1.0%.<xref ref-type="bibr" rid="article-30636.r4">[4]</xref></p>
        <p>The lower concentration of 0.5% produced less ocular discomfort with the same efficacy in dilating the pupil as the 1% solution in a study on 30 adolescents (aged 12&#x000a0;to 18 years) with type 1 diabetes.<xref ref-type="bibr" rid="article-30636.r5">[5]</xref>&#x000a0;Conversely, the higher concentration is typically used in adults and&#x000a0;in eyes that dilate poorly, such as those&#x000a0;with pigmented iris, peripheral iridotomy, and posterior synechia. Tropicamide binds with pigment and may take longer to act on darker irises.<xref ref-type="bibr" rid="article-30636.r6">[6]</xref> Interestingly, one pilot study that evaluated the use of multiple drops of tropicamide concluded that a single drop of 0.5% is not inferior to two drops of 0.5% in pigmented eyes.<xref ref-type="bibr" rid="article-30636.r7">[7]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Intended for diagnostic purposes: cycloplegia</p>
          </list-item>
        </list>
        <p>Eyecare specialists are interested in accommodation paralysis, also known as cycloplegia, when determining a patient's refractive error. Cycloplegic agents inactivate the ciliary muscle, so the patient cannot influence the refractive measurement. For example, an accurate evaluation is necessary before LASIK (laser-assisted in situ keratomileuses) surgery. In a 2017 meta-analysis, the more popular cycloplegic drug of choice, cyclopentolate, was compared to tropicamide. The research concluded that tropicamide is a viable alternative.<xref ref-type="bibr" rid="article-30636.r8">[8]</xref></p>
        <p>
<bold>FDA Non-approved, Off-label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Parkinson Disease</p>
          </list-item>
        </list>
        <p>The properties of anticholinergics can counter the imbalanced dopaminergic to cholinergic activity in neurological disorders such as Parkinson's disease. One randomized pilot study observed the safety and efficacy of tropicamide reduce sialorrhea in neurodegenerative diseases. Tropicamide was given orally as a dissolving film. Although the small sample size limited the power, a significant decrease in perceived symptoms on the visual analog scale and saliva volume measured with cotton balls occurred.<xref ref-type="bibr" rid="article-30636.r9">[9]</xref>&#x000a0;Tropicamide may have a role in alleviating the characteristic tremor exhibited by patients with Parkinsonism.</p>
      </sec>
      <sec id="article-30636.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Mechanism for Dilation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As a parasympathetic antagonist, tropicamide exerts its dilatory effects by acting on the pupillary sphincter muscle to cause its relaxation.<xref ref-type="bibr" rid="article-30636.r10">[10]</xref>&#x000a0; Like other anticholinergic agents, tropicamide inhibits the parasympathetic drive, allowing sympathetic actions to dominate.<xref ref-type="bibr" rid="article-30636.r11">[11]</xref>&#x000a0; As the radial muscles of the iris (dilator pupillae), which are innervated by the sympathetic nervous system, are unaffected, they contract and cause the pupil to dilate. Its optimal effect occurs 25 to 30 minutes post-administration.<xref ref-type="bibr" rid="article-30636.r12">[12]</xref> Typically, mydriasis reverses within 4 to 8 hours. However, it may take 24 hours for the mydriatic effect to wear off in some individuals. Weaker strength may cause mydriasis with little cycloplegia.</p>
          </list-item>
        </list>
        <p>
<bold>Mechanism for Cycloplegia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Accommodation becomes hindered when tropicamide blocks the muscarinic receptors of the ciliary body. Its cycloplegic effect can last anywhere from 4 to 10 hours, with the onset of action occurring within 20 to 30 minutes.<xref ref-type="bibr" rid="article-30636.r13">[13]</xref>&#x000a0;This leads to reduced near vision.</p>
          </list-item>
        </list>
        <p>
<bold>The mechanism for Reduction of Sialorrhea</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inhibition of the muscarinic acetylcholine receptors on salivary glands is responsible for decreasing hypersalivation in patients with Parkinson's disease.<xref ref-type="bibr" rid="article-30636.r9">[9]</xref><xref ref-type="bibr" rid="article-30636.r14">[14]</xref> Its potential therapeutic utility is because it is relatively selective for M4 receptors.<xref ref-type="bibr" rid="article-30636.r15">[15]</xref> Researchers have seen promising results in abolishing drug-induced tremulous jaw movement in rodent models.<xref ref-type="bibr" rid="article-30636.r15">[15]</xref> Future studies will&#x000a0;be necessary to determine if the tremorolytic effects can be clinically useful and extended to man.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30636.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Administration requires the removal of contact lenses. This topical ophthalmic solution is instilled into the eye in droplet form. The lacrimal sac should be compressed with the&#x000a0;fingertip&#x000a0;for 2 to 3 minutes after administration to reduce systemic absorption and systemic adverse effects. The tip of the dropper should not touch any surface as it might contaminate the drug. In a child, ensure the drug does not get to their mouth. Hands require washing before and after instilling the drop. The individual should avoid driving and not engage in potentially hazardous activities during pupillary dilation. After pupillary dilation, sensitivity to light may occur, and sunglasses may be necessary.</p>
        <p>An infrequently used option is spray application. Several studies have shown that using tropicamide in its vaporized form is just as effective in achieving increased pupil diameter but with less patient-reported discomfort.<xref ref-type="bibr" rid="article-30636.r16">[16]</xref><xref ref-type="bibr" rid="article-30636.r17">[17]</xref><xref ref-type="bibr" rid="article-30636.r18">[18]</xref> In a randomized clinical trial, researchers concluded that administration via an ophthalmic insert, Mydriasert (containing 5.4 mg of phenylephrine hydrochloride and&#x000a0;0.28 mg of tropicamide), was safe and effective for use in neonates.<xref ref-type="bibr" rid="article-30636.r19">[19]</xref></p>
        <p>Along with the active ingredient (tropicamide), the drop has multiple inactive ingredients. These include benzalkonium chloride (preservative), purified water, edetate disodium dihydrate, and boric acid. Hydrochloric acid and/or sodium&#x000a0;hydroxide are used to adjust pH to 4.0 to 5.8.&#x000a0;For refraction, one drop of tropicamide 1% is put in each eye 5 minutes apart. For examination of the fundus, 0.5% strength is an option. Tropicamide may dilate pupils in acute anterior uveitis, and one drop every 5 to 10 minutes should optimally dilate the pupil.</p>
      </sec>
      <sec id="article-30636.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Ocular adverse events include transient stinging, photophobia, superficial punctate keratitis, blurred vision, and a rise in intraocular pressure.</p>
        <p>Potential anticholinergic effects include dry mouth, high temperature, constipation, increased heart rate, and headache. Young children and the elderly are most susceptible to these side effects. Fortunately, due to its low affinity for muscarinic receptors and very low receptor occupancy in plasma, tropicamide applied as an eye drop rarely causes the systemic effects listed above.<xref ref-type="bibr" rid="article-30636.r20">[20]</xref>&#x000a0;The use of anticholinergic drugs carries a small risk of central nervous system (CNS) disturbance, including psychotic reactions and behavioral problems.<xref ref-type="bibr" rid="article-30636.r21">[21]</xref></p>
        <p>Serious adverse events, especially vasomotor and cardiorespiratory collapse, behavioral changes, and psychotic reactions, have been reported rarely in children with the use of anticholinergic drugs, especially cyclopentolate.<xref ref-type="bibr" rid="article-30636.r22">[22]</xref>&#x000a0;Phenylephrine present in some mydriatic drops can cause systemic arterial hypertension, arrhythmia, tachycardia, myocardial infarction, syncope, and subarachnoid hemorrhage, and caution should be exercised while using these eye drops in preterm low birthweight babies or elderly patients with cardiovascular risk factors.<xref ref-type="bibr" rid="article-30636.r23">[23]</xref>&#x000a0;The medicine should remain out of the reach of children. Other side&#x000a0;effects include nausea, vomiting, pallor, allergic reactions, and muscular rigidity.<xref ref-type="bibr" rid="article-30636.r24">[24]</xref>&#x000a0;</p>
        <p>Precipitating angle closure in primary open-angle glaucoma patients, as well as the potential increase in intraocular pressure after mydriasis, is a frequent concern to many ophthalmologists.<xref ref-type="bibr" rid="article-30636.r25">[25]</xref> However, multiple studies involving high-risk groups demonstrated that the incidence is relatively low, and the risk of underdiagnosing vision-threatening diseases should be prioritized.<xref ref-type="bibr" rid="article-30636.r26">[26]</xref> The importance of getting a clear view of the fundus should not be undermined. Nonetheless, clinicians should carefully monitor and educate at-risk patients&#x000a0;regarding what symptoms to look out for, such as headache and eye pain. Pupillary dilation should be avoided in fellow eyes of acute angle closure glaucoma until an open peripheral iridotomy is ensured.&#x000a0;Tropicamide is a category C drug in pregnancy, and it is unknown whether it is excreted in human milk.&#x000a0;</p>
        <p><bold>Allergic contact dermatitis or allergic blepharoconjunctivitis&#x000a0;</bold>due to mydriatics:</p>
        <p>Allergic contact dermatitis has been reported with phenylephrine<xref ref-type="bibr" rid="article-30636.r27">[27]</xref> and less commonly with tropicamide,&#x000a0;though the preservative agent, benzalkonium chloride, may also be responsible.<xref ref-type="bibr" rid="article-30636.r28">[28]</xref>&#x000a0;Methods to&#x000a0;detect the offending agent include a skin patch test and conjunctival challenge test.<xref ref-type="bibr" rid="article-30636.r29">[29]</xref>&#x000a0;The conjunctival challenge test&#x000a0;was shown to be safe and useful.<xref ref-type="bibr" rid="article-30636.r29">[29]</xref> The conjunctival challenge test&#x000a0;may detect the allergy when the skin patch test is negative.<xref ref-type="bibr" rid="article-30636.r29">[29]</xref>&#x000a0;A study on 37 patients with acute conjunctivitis after using mydriatic eye drops found phenylephrine to be the offending agent in 93.5% of cases, and one patient had an allergy to preservatives.<xref ref-type="bibr" rid="article-30636.r29">[29]</xref>&#x000a0;The allergic reaction to phenylephrine starts at around 3&#x000a0;to 4 hours and gradually subsides in 72 hours.<xref ref-type="bibr" rid="article-30636.r30">[30]</xref> Management includes avoidance or stoppage of the offending agent and topical and/or systemic steroids/antiallergics. Such patients should be informed about the allergy, and the medical records should highlight this boldly so that the offending agent is avoided in future visits.</p>
      </sec>
      <sec id="article-30636.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity to any active/inactive ingredient constitutes a contraindication for its use. There have been no studies on tropicamide use during breastfeeding, but nursing mothers can reduce the amount that reaches the nasolacrimal duct&#x000a0;by applying pressure to the&#x000a0;lacrimal sac&#x000a0;for some time (at least 1 minute) and wiping away any excess solution.<xref ref-type="bibr" rid="article-30636.r31">[31]</xref></p>
      </sec>
      <sec id="article-30636.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There are no recommended diagnostic exams for monitoring the use of tropicamide. Pupillary dilation and dimness of near vision denote that the drug's action has started. If the pupil reacts to light, that means that the pupil is not fully dilated, and more time or more administration of tropicamide eye drops is needed for the maximal action to come.</p>
      </sec>
      <sec id="article-30636.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Although tropicamide is a short-acting drug, and the frequency of associated adverse events is rare, there are certain instances when reversal of mydriasis is necessary, including decreasing the risk of angle-closure glaucoma, improving blurry vision, and decreasing recovery time for patient comfort. Presumably, a cholinergic agent like pilocarpine should be able to undo the effects of an anticholinergic drug. However, several studies have reported conflicting pupillary responses.<xref ref-type="bibr" rid="article-30636.r32">[32]</xref><xref ref-type="bibr" rid="article-30636.r33">[33]</xref><xref ref-type="bibr" rid="article-30636.r26">[26]</xref><xref ref-type="bibr" rid="article-30636.r34">[34]</xref> At times, only a partial reversal was observed.<xref ref-type="bibr" rid="article-30636.r35">[35]</xref></p>
        <p>A study of 23 healthy subjects demonstrated that pilocarpine had an insignificant impact on returning pupil diameter to baseline. Seventeen percent of subjects reportedly had a reduction in visual acuity, indicating that pilocarpine use is futile and possibly detrimental.<xref ref-type="bibr" rid="article-30636.r33">[33]</xref> For these reasons, its use after tropicamide-induced dilation has not gained wide acceptance. Alternatively, an adrenergic blocking agent, such as dapiprazole (0.5% eye drop) or moxisylyte (thymoxamine), can be used. This class of drugs exerts its effect by causing relaxation of the dilator muscle.<xref ref-type="bibr" rid="article-30636.r35">[35]</xref>&#x000a0;</p>
        <p>The use of dapiprazole can cut recovery time in half compared to waiting for tropicamide to wear off on its own.<xref ref-type="bibr" rid="article-30636.r36">[36]</xref>&#x000a0;Unfortunately, FDA has removed dapiprazole from the market for reasons unrelated to safety and efficacy. Currently, there are no approved methods of reversing tropicamide-induced mydriasis, and patients should wear sunglasses to mitigate light sensitivity.</p>
      </sec>
      <sec id="article-30636.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Intravenous injection of tropicamide and other eye drops is a non-clinical use that has been on the rise in polydrug misusers. A recently published review describes factors such as low cost, easy access, and enhancement of heroin's effects as reasons for its misuse.<xref ref-type="bibr" rid="article-30636.r37">[37]</xref> Healthcare professionals should be informed to recognize better high-risk populations of drug users and patients with psychiatric disorders.</p>
        <p>There is limited information on interprofessional communication and tropicamide, as the absence of associated adverse events is well established. Nonetheless, coordinated care between the interprofessional healthcare team, including the pharmacist, optician, nurse practitioner, and ophthalmologist, ensures better outcomes. Suggestions for improvement include proper medication documentation and routine patient education. The use of tropicamide in the clinical setting requires an interprofessional approach, including&#x000a0;open communication and accurate record keeping, with each caregiver&#x000a0;operating in a team structure that leads to optimal patient results and minimizes adverse events. [Level 5]</p>
      </sec>
      <sec id="article-30636.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30636&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30636">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30636/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30636">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30636.s11">
        <title>References</title>
        <ref id="article-30636.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chuck</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Flaxel</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gedde</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mah</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Musch</surname>
                <given-names>DC</given-names>
              </name>
              <collab>American Academy of Ophthalmology Preferred Practice Pattern Committee</collab>
            </person-group>
            <article-title>Comprehensive Adult Medical Eye Evaluation Preferred Practice Pattern&#x000ae;.</article-title>
            <source>Ophthalmology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>P1</fpage>
            <page-range>P1-P29</page-range>
            <pub-id pub-id-type="pmid">34933742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shukla</surname>
                <given-names>UV</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Diabetic Retinopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32809640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mamalis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Importance of pupil dilation for cataract surgery.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2017</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>583</fpage>
            <page-range>583-584</page-range>
            <pub-id pub-id-type="pmid">28602315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grob</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gonzalez-Gonzalez</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>1281</fpage>
            <page-range>1281-9</page-range>
            <pub-id pub-id-type="pmid">25061276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassler-Hurst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wadham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rayman</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A double-blind study comparing 0.5% and 1% tropicamide for annual retinal screening in diabetic adolescents.</article-title>
            <source>Diabet Med</source>
            <year>2004</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>434</fpage>
            <page-range>434-9</page-range>
            <pub-id pub-id-type="pmid">15089787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Manny</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Fern</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Comparison of two drug combinations for dilating dark irides.</article-title>
            <source>Optom Vis Sci</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-4</page-range>
            <pub-id pub-id-type="pmid">20035241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siderov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nurse</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The mydriatic effect of multiple doses of tropicamide.</article-title>
            <source>Optom Vis Sci</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>82</volume>
            <issue>11</issue>
            <fpage>955</fpage>
            <page-range>955-8</page-range>
            <pub-id pub-id-type="pmid">16317370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazdani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Momeni-Moghaddam</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zarifmahmoudi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ehsaei</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of cyclopentolate versus tropicamide cycloplegia: A systematic review and meta-analysis.</article-title>
            <source>J Optom</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-143</page-range>
            <pub-id pub-id-type="pmid">29132914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lloret</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Nano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carrosella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gamzu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merello</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients.</article-title>
            <source>J Neurol Sci</source>
            <year>2011</year>
            <month>Nov</month>
            <day>15</day>
            <volume>310</volume>
            <issue>1-2</issue>
            <fpage>248</fpage>
            <page-range>248-50</page-range>
            <pub-id pub-id-type="pmid">21636098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>The comparison of mydriatic effect between two drugs of different mechanism.</article-title>
            <source>Korean J Ophthalmol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-2</page-range>
            <pub-id pub-id-type="pmid">19337478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Evidence for a neuropathic aetiology in the small pupil of diabetes mellitus.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">6821679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pukrushpan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tulvatana</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kulvichit</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Intraocular pressure change following application of 1% tropicamide for diagnostic mydriasis.</article-title>
            <source>Acta Ophthalmol Scand</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-70</page-range>
            <pub-id pub-id-type="pmid">16637852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofmeister</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaupp</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Schallhorn</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Comparison of tropicamide and cyclopentolate for cycloplegic refractions in myopic adult refractive surgery patients.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>694</fpage>
            <page-range>694-700</page-range>
            <pub-id pub-id-type="pmid">15899444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Futatsugi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kusakawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Manabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taketo</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mikoshiba</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation in mice.</article-title>
            <source>J Physiol</source>
            <year>2004</year>
            <month>Jul</month>
            <day>15</day>
            <volume>558</volume>
            <issue>Pt 2</issue>
            <fpage>561</fpage>
            <page-range>561-75</page-range>
            <pub-id pub-id-type="pmid">15146045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Burgos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Salamone</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>194</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-59</page-range>
            <pub-id pub-id-type="pmid">17594079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Portes</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>de Mello</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cavalcanti</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>632</fpage>
            <page-range>632-5</page-range>
            <pub-id pub-id-type="pmid">22775152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparison of mydriatic efficacy of spray application and drop instillation of tropicamide 1%.</article-title>
            <source>Eye (Lond)</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>13 ( Pt 5)</volume>
            <fpage>653</fpage>
            <page-range>653-5</page-range>
            <pub-id pub-id-type="pmid">10696320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Topical mydriatic and cycloplegic spray for Chinese children.</article-title>
            <source>J Pediatr Ophthalmol Strabismus</source>
            <year>2003</year>
            <season>Nov-Dec</season>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>349</fpage>
            <page-range>349-52</page-range>
            <pub-id pub-id-type="pmid">14655983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bremond-Gignac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jacqz-Aigrain</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abdoul</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Daruich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beresniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baud</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>C</given-names>
              </name>
              <collab>on&#x000a0;behalf&#x000a0;of&#x000a0;the&#x000a0;CLAIR&#x000a0;FO&#x000a0;Study&#x000a0;Group</collab>
            </person-group>
            <article-title>Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial.</article-title>
            <source>Neonatology</source>
            <year>2019</year>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-148</page-range>
            <pub-id pub-id-type="pmid">30481790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vuori</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kaila</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iisalo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saari</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Systemic absorption and anticholinergic activity of topically applied tropicamide.</article-title>
            <source>J Ocul Pharmacol</source>
            <year>1994</year>
            <season>Summer</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>431</fpage>
            <page-range>431-7</page-range>
            <pub-id pub-id-type="pmid">8083562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Minderhout</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Joosse</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Grootendorst</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Schalij-Delfos</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Adverse reactions following routine anticholinergic eye drops in a paediatric population: an observational cohort study.</article-title>
            <source>BMJ Open</source>
            <year>2015</year>
            <month>Dec</month>
            <day>23</day>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e008798</fpage>
            <pub-id pub-id-type="pmid">26700273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kodsi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gaffar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Cardiopulmonary arrest following administration of Cyclomydril eyedrops for outpatient retinopathy of prematurity screening.</article-title>
            <source>J AAPOS</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-4</page-range>
            <pub-id pub-id-type="pmid">24698618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiuey</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular effects of commonly used ophthalmic medications.</article-title>
            <source>Clin Cardiol</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-8</page-range>
            <pub-id pub-id-type="pmid">8903532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wahl</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Systemic reaction to tropicamide.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1969</year>
            <month>Sep</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-1</page-range>
            <pub-id pub-id-type="pmid">5806055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavanya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baskaran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Risk of acute angle closure and changes in intraocular pressure after pupillary dilation in Asian subjects with narrow angles.</article-title>
            <source>Ophthalmology</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>474</fpage>
            <page-range>474-80</page-range>
            <pub-id pub-id-type="pmid">22118999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pandit</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mydriasis and glaucoma: exploding the myth. A systematic review.</article-title>
            <source>Diabet Med</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>693</fpage>
            <page-range>693-9</page-range>
            <pub-id pub-id-type="pmid">11110501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raison-Peyron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Du Thanh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillot</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Long-lasting allergic contact blepharoconjunctivitis to phenylephrine eyedrops.</article-title>
            <source>Allergy</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>657</fpage>
            <page-range>657-8</page-range>
            <pub-id pub-id-type="pmid">19254293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boukhman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Allergic contact dermatitis from tropicamide ophthalmic solution.</article-title>
            <source>Contact Dermatitis</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-8</page-range>
            <pub-id pub-id-type="pmid">10416714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villarreal</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Reliability of diagnostic tests for contact allergy to mydriatic eyedrops.</article-title>
            <source>Contact Dermatitis</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>150</fpage>
            <page-range>150-4</page-range>
            <pub-id pub-id-type="pmid">9536407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geyer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yust</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Allergic blepharoconjunctivitis due to phenylephrine.</article-title>
            <source>J Ocul Pharmacol</source>
            <year>1988</year>
            <season>Summer</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-6</page-range>
            <pub-id pub-id-type="pmid">3171335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Tropicamide</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>4</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30000733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anastasi</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ogle</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>TP</given-names>
              </name>
            </person-group>
            <article-title>Effect of pilocarpine in counteracting mydriasis.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1968</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>710</fpage>
            <page-range>710-5</page-range>
            <pub-id pub-id-type="pmid">5652262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Orton</surname>
                <given-names>HP</given-names>
              </name>
            </person-group>
            <article-title>Counteracting the effects of mydriatics. Does it benefit the patient?</article-title>
            <source>Arch Ophthalmol</source>
            <year>1987</year>
            <month>Apr</month>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>486</fpage>
            <page-range>486-9</page-range>
            <pub-id pub-id-type="pmid">3566601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mapstone</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Dilating dangerous pupils.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1977</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>517</fpage>
            <page-range>517-24</page-range>
            <pub-id pub-id-type="pmid">143952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doughty</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lyle</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>A review of the clinical pharmacokinetics of pilocarpine, moxisylyte (thymoxamine), and dapiprazole in the reversal of diagnostic pupillary dilation.</article-title>
            <source>Optom Vis Sci</source>
            <year>1992</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>358</fpage>
            <page-range>358-68</page-range>
            <pub-id pub-id-type="pmid">1350669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molinari</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Dapiprazole clinical efficiency for counteracting tropicamide 1%.</article-title>
            <source>Optom Vis Sci</source>
            <year>1994</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>319</fpage>
            <page-range>319-22</page-range>
            <pub-id pub-id-type="pmid">7915025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30636.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bersani</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Imperatori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Prilutskaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuliev</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Injecting eye-drops: a mini-review on the non-clinical use of tropicamide.</article-title>
            <source>Hum Psychopharmacol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>262</fpage>
            <page-range>262-4</page-range>
            <pub-id pub-id-type="pmid">26216560</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
